Can tech groups sustain their growth as US and China slow down?

Tech not immune from growth concerns

clock • 2 min read

The technology sector may be better-placed over the long-term to deliver structural growth, but it is not immune from these concerns. Investors are correctly asking whether certain technology groups can sustain growth.

The market has, for some time, assumed certain companies could sustain growth rates of 30%-50% indefinitely. However, we are now starting to see limits to that growth, particularly among some medium-sized companies such as Yelp, Pandora, GrubHub and Twitter. While revenue growth has continued, growth in user numbers has stalled. The most recent example was Twitter - it saw its user growth stall in the final quarter of 2015, with 320 million average active users monthly. This was the first time in its history that monthly active users had not grown.  Time for fund groups to practice...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot